Rationale for treatment durations of targeted cancer agents

The Lancet Oncology

Volumn 11, Issue 12, 2010, Pages 1113-1115

  Pearson, Sallie Anne ^a   Chin, Melvin ^a,b   Faedo, Margaret ^a   Ward, Robyn ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LAPATINIB; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; CYTOTOXICITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; FUNDING; HEALTH CARE COST; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HEALTH CARE COSTS; HUMANS; NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78649632214     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70236-9     Document Type: Letter

References (10)

1. Fox E, Curt GA, Balis FM Clinical trial design for target-based therapy. Oncologist 2002, 7:401-409.
2. Gutierrez ME, Kummar S, Giaccone G Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 2009, 6:259-265.
3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
4. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820. for the FinHer Study Investigators.
5. Spielmann M, Roché H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009, 27:6129-6134.
6. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (A-CT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005, 94(supp 1):S5.
7. Robert NJ, Eiermann W, Pienkowski T, et al. BCIRG 006: docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: quality of life (QOL) at 36 months follow-up. Proc Soc Am Clin Oncol 2007, 25(suppl):19647. for the BCIRG 006 investigators, (abstr).
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672. for the Herceptin Adjuvant (HERA) Trial study team.
9. Guarneri V, Frassoldati A, Bruzzi P, D'Amico, et al. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2-positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer 2008, 8:453-456.
10. Abbasi K Compulsory registration of clinical trials. BMJ 2004, 329:637-638.